RNA250117C36000
- 1.40
- 0.000.00%
Avidity Biosciences Newsroom
H.C. Wainwright Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $72
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
What 8 Analyst Ratings Have To Say About Avidity Biosciences
Avidity Biosciences Initiated at Buy by HC Wainwright & Co.
Avidity Biosciences Price Target Announced at $72.00/Share by HC Wainwright & Co.
Avidity Biosciences Insider Sold Shares Worth $831,605, According to a Recent SEC Filing
PepGen Stock Craters 35% on FDA Clinical Hold
Avidity Biosciences (RNA) Receives a Buy From TD Cowen
Avidity Biosciences: Advancing Clinical Programs With Strategic Focus and Growth Potential
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Avidity Biosciences to Participate in Upcoming Investor Conference
RBC Capital Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $67
Express News | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA Stock Hits Record High on Entering the Cardiac Disease Space
Avidity Biosciences: Expanding Horizons in Precision Cardiology With New Genetic Targets
Avidity Biosciences Price Target Maintained With a $65.00/Share by Chardan Capital
Avidity Biosciences Is Maintained at Buy by Chardan Capital
Avidity Biosciences Jumps 16%; Reaches All-time High
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $78